Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...

Patients with vs without keloids had a higher prevalence of interstitial lung disease after controlling for patient specific factors.

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...

A panel of experts, including Dr Rohit Aggarwal, Principal Investigator of the decentralized Myositis Interstitial Lung ...

Nine leading patient organizations are uniting to present the fourth annual ILD Day on Wednesday, Sept. 18, to raise ...

Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital, shares critical insights into the risk factors and management of interstitial lung ...

18, to raise awareness and understanding of interstitial lung disease (ILD) and pulmonary fibrosis (PF). ILD encompasses a large group of more than 200 diseases characterized by inflammation and ...